Deacon CF - Search Results

1

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.

Wewer Albrechtsen NJ, Møller A, Martinussen C, Gluud LL, Rashu EB, Richter MM, Plomgaard P, Goetze JP, Kjeldsen S, Hansen LH, Gustafsson F, Deacon CF, Holst JJ, Madsbad S, Bojsen-Møller KN. Wewer Albrechtsen NJ, et al. Among authors: deacon cf. Diabetes Obes Metab. 2022 Oct;24(10):2017-2026. doi: 10.1111/dom.14789. Epub 2022 Jul 21. Diabetes Obes Metab. 2022. PMID: 35676803 Free PMC article. Clinical Trial.

2

Human colon produces fully processed glucagon-like peptide-1 (7-36) amide.

Deacon CF, Johnsen AH, Holst JJ. Deacon CF, et al. FEBS Lett. 1995 Sep 25;372(2-3):269-72. doi: 10.1016/0014-5793(95)00983-g. FEBS Lett. 1995. PMID: 7556682 Free article.

3

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.

Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Deacon CF, et al. Diabetes. 1995 Sep;44(9):1126-31. doi: 10.2337/diab.44.9.1126. Diabetes. 1995. PMID: 7657039

4

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon CF, Johnsen AH, Holst JJ. Deacon CF, et al. J Clin Endocrinol Metab. 1995 Mar;80(3):952-7. doi: 10.1210/jcem.80.3.7883856. J Clin Endocrinol Metab. 1995. PMID: 7883856

5

Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma.

Pridal L, Deacon CF, Kirk O, Christensen JV, Carr RD, Holst JJ. Pridal L, et al. Among authors: deacon cf. Eur J Drug Metab Pharmacokinet. 1996 Jan-Mar;21(1):51-9. doi: 10.1007/BF03190278. Eur J Drug Metab Pharmacokinet. 1996. PMID: 8839678

6

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.

Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Deacon CF, et al. Am J Physiol. 1996 Sep;271(3 Pt 1):E458-64. doi: 10.1152/ajpendo.1996.271.3.E458. Am J Physiol. 1996. PMID: 8843738

7

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.

Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Deacon CF, et al. Diabetologia. 1998 Mar;41(3):271-8. doi: 10.1007/s001250050903. Diabetologia. 1998. PMID: 9541166

8

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

Deacon CF, Hughes TE, Holst JJ. Deacon CF, et al. Diabetes. 1998 May;47(5):764-9. doi: 10.2337/diabetes.47.5.764. Diabetes. 1998. PMID: 9588448

9

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

Holst JJ, Deacon CF. Holst JJ, et al. Among authors: deacon cf. Diabetes. 1998 Nov;47(11):1663-70. doi: 10.2337/diabetes.47.11.1663. Diabetes. 1998. PMID: 9792533 Review.

10

On the treatment of diabetes mellitus with glucagon-like peptide-1.

Holst JJ, Deacon C, Toft-Nielsen MB, Bjerre-Knudsen L. Holst JJ, et al. Ann N Y Acad Sci. 1998 Dec 11;865:336-43. doi: 10.1111/j.1749-6632.1998.tb11193.x. Ann N Y Acad Sci. 1998. PMID: 9928027 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

228 results

Search Page